Movers and SHAKERS
ProMIS Neurosciences (PMN:CA)
A door opens in the treatment for Alzheimer's.
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques.
- Competitor discontinues development. Biogen (BIIB: Not Rated), a competing company in the Alzheimer's area, this morning announced the decision to discontinue clinical development of aducanumab. Biogen is discontinuing two Phase III clinical trials evaluating the efficacy and safety of aducanumab for the treatment of Alzheimer's patients.
- Skepticism to heighten. We believe the negative news will fuel skepticism among
investors looking to deploy capital in Alzheimer's area. The failure of Biogen
adds to a string of disappointing results in hum...
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.